Ed Rosen is a serial entrepreneur with a foundation of success in multinational drug, device and diagnostic companies. Mr. Rosen is currently an Executive in Residence for the Technology Ventures Group at Columbia University and is the founder of Glendevon Life Sciences LLC.
Ed was the founding CEO, President, Chief Executive Officer and a Director of Elucida Oncology, Inc. and has a passion towards driving companies and the people within to fulfill their true potential. Over the last four years, he created the licensing, infrastructure, strategy and team for Elucida Oncology to thrive while attracting a world-class Board and achieving significant Series A financing.
Mr. Rosen has more than 20 years of operational and leadership experience in the life sciences industry. Prior to Elucida, he enjoyed a stellar career across a number of companies within Johnson & Johnson. As Worldwide Vice President of Marketing for a large surgical division, he developed an entirely new business model while overseeing the development of the leading direct to patient web presence in the industry. He co-led the re-birth of an immunology / oncology division setting it on a valuation journey from less than $100MM to $1.3Bn in five years. As Director of Health Economics and Reimbursement & Strategy for a large peripheral vascular division, Ed played an industry leading role in several national coverage determinations and developed a keen understanding of economic outcomes to add to his existing clinical trial design experience. As a marketer, he took a market-leading product suddenly and incorrectly facing an unheard-of level of attack from competition, regulators and clinicians and doubled revenue from the previous #1 market share position.
Prior to Johnson & Johnson, Ed started his career with Smith & Nephew, plc, with roles in the United Kingdom and United States, including marketing, operations, technology transfer and sales.
Mr. Rosen holds a Bachelor of Arts with Honors in Business from the University of Lincoln in the United Kingdom.
Areas of Expertise Include:
o Start-up CEO.
o Clinical fields including oncology, cardiovascular, immune-mediated disease and precision medicine.
o Market and IP assessment including health economics and reimbursement.
o Success across device, drug and diagnostics, with a focus on combination products.
o US and Global markets.
o Frequent speaker on precision medicine, precision oncology, entrepreneurship and the NY life sciences ecosystem.